- Home
- UTSI vs BCAB Comparison
UTSI vs BCAB Comparison
Compare UTSI & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTSI
- BCAB
- Stock Information
- Founded
- UTSI 1991
- BCAB 2007
- Country
- UTSI China
- BCAB United States
- Employees
- UTSI N/A
- BCAB N/A
- Industry
- UTSI Telecommunications Equipment
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- UTSI Telecommunications
- BCAB Health Care
- Exchange
- UTSI Nasdaq
- BCAB Nasdaq
- Market Cap
- UTSI 24.9M
- BCAB 22.3M
- IPO Year
- UTSI 2000
- BCAB 2020
- Fundamental
- Price
- UTSI $2.67
- BCAB $0.39
- Analyst Decision
- UTSI
- BCAB Buy
- Analyst Count
- UTSI 0
- BCAB 2
- Target Price
- UTSI N/A
- BCAB $1.00
- AVG Volume (30 Days)
- UTSI 5.9K
- BCAB 550.8K
- Earning Date
- UTSI 09-04-2025
- BCAB 08-07-2025
- Dividend Yield
- UTSI N/A
- BCAB N/A
- EPS Growth
- UTSI N/A
- BCAB N/A
- EPS
- UTSI N/A
- BCAB N/A
- Revenue
- UTSI $10,878,000.00
- BCAB $11,000,000.00
- Revenue This Year
- UTSI N/A
- BCAB N/A
- Revenue Next Year
- UTSI N/A
- BCAB N/A
- P/E Ratio
- UTSI N/A
- BCAB N/A
- Revenue Growth
- UTSI N/A
- BCAB N/A
- 52 Week Low
- UTSI $1.84
- BCAB $0.24
- 52 Week High
- UTSI $3.22
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- UTSI 57.72
- BCAB 52.08
- Support Level
- UTSI $2.65
- BCAB $0.36
- Resistance Level
- UTSI $2.79
- BCAB $0.42
- Average True Range (ATR)
- UTSI 0.16
- BCAB 0.03
- MACD
- UTSI 0.02
- BCAB 0.00
- Stochastic Oscillator
- UTSI 57.27
- BCAB 71.57
About UTSI UTStarcom Holdings Corp.
UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.